Bilcare Ltd Stock Price Today (NSE: BI)

Bilcare Ltd

58.00+0.48 (+0.83%)
Market Closed

Fundamental Score

...

Bilcare Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis

Bilcare Ltd share price today is 58.00, up +0.83% on NSE/BSE as of 17 June 2026. Bilcare Ltd (BI) is a Small-cap company in the Healthcare Research, Analytics & Technology sector with a market capitalisation of 200.42 (Cr). The 52-week high for BI share price is 116.00 and the 52-week low is 50.00. The company has a Return on Equity (ROE) of -5.58% and a debt-to-equity ratio of 1.48.

Bilcare Ltd Share Price Chart — NSE/BSE Historical Performance

No data
High
74.00
Low
58.00
Volume
5.6K
Change
-1.03%

Bilcare Ltd share price chart: -1.03% return over the past month. 52-week high ₹116.00, 52-week low ₹50.00.

Bilcare Ltd — Last 10 Trading Days

DateOpenHighLowCloseVolume
63.1966.5061.9066.025.32K (Cr)
70.0070.0063.1063.208.39K (Cr)
63.5064.0062.0462.062.10K (Cr)
62.5063.3362.2062.201.15K (Cr)
61.5062.5061.0062.124.36K (Cr)
65.0066.7060.0561.5911.09K (Cr)
64.8064.8062.5663.99627.00 (Cr)
64.0566.0062.6463.011.22K (Cr)
62.0765.9562.0763.801.56K (Cr)
65.0066.4562.6163.046.82K (Cr)

Bilcare Ltd — Last 12 Months Price History

MonthOpenHighLowCloseChange
70.0070.0061.9066.02-5.69%
66.6074.0060.0562.06-6.82%
52.8064.8052.8060.24+14.09%
58.0062.2750.0052.76-9.03%
64.8570.8957.5158.27-10.15%
80.7080.7763.0167.20-16.73%
83.0087.7975.4079.67-4.01%
108.00108.0076.1585.50-20.83%
84.95116.0081.40104.78+23.34%
69.00100.9966.1082.39+19.41%
71.9975.3063.0069.38-3.63%
73.2580.0067.1569.04-5.75%

Returns & Performance

Poor

Return on Equity (ROE)

-5.58%

Profit generated per ₹1 of shareholder equity

Poor

Return on Capital (ROCE)

1.10%

Returns generated on total capital deployed

Poor

Oper. Profit Margin (5Y Avg)

6.33%

Average operating profit margin over 5 years

Dividend Yield

0.00%

Annual dividend as % of current share price

Bilcare Ltd Valuation Check

Price to Earnings (P/E)

N/A

Share price ÷ earnings per share. Lower = cheaper

Poor

Industry Avg P/E

45.95x

Average P/E of all peers in this sector

Market-cap Classification
Small-cap
Higher growth potential with higher volatility.

Shareholding Pattern

Excellent

Promoter Holding

30.02%

% shares held by company founders/management

Poor

FII Holding

0.04%

% shares held by foreign institutional investors

Poor

DII Holding

0.00%

% held by domestic mutual funds, LIC, banks

Poor

Promoter Pledged %

1.39%

% of promoter shares pledged as collateral — lower is safer

Growth Engine

Poor

Profit Growth (Quarterly YoY)

-15.39%

Net profit growth vs same quarter last year

Poor

Revenue Growth (Quarterly YoY)

-11.67%

Revenue growth vs same quarter last year

Poor

Revenue Growth (5-Year CAGR)

-15.48%

Compounded annual revenue growth over 5 years

Excellent

EPS Growth (5-Year CAGR)

13.81%

Earnings per share growth over 5 years

Excellent

Net Profit Growth (5-Year CAGR)

13.81%

Compounded annual net profit growth over 5 years

Balance Sheet Health

Poor

Debt to Equity Ratio

1.48x

Total debt ÷ equity. Below 0.5 = financially healthy

Poor

Interest Coverage Ratio

0.09x

EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably

Free Cash Flow (5-Year Total)

222.32 (Cr)

Cash left after capex over 5 years. Positive = self-funded growth

Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice

Bilcare Ltd Fundamental Analysis & Valuation Benchmarking

Educational evaluation of BI across key market metrics for learning purposes.

Positive Indicators

1 factors identified

Strong Cash Generation (₹222.32 Cr over 5Y)

Observation: Healthy free cash flow generation supports growth and returns.

Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.

Risk Factors

9 factors identified

Below-Average Return on Equity (-5.58%)

Observation: Returns on equity are below industry benchmarks.

Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.

Suboptimal ROCE (1.10%)

Observation: Returns on capital employed are below expectations.

Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.

Profit Decline Concern (-15.39%)

Observation: Significant year-over-year profit contraction observed.

Analysis: Declining profitability requires investigation into underlying causes.

Revenue Contraction (-11.67%)

Observation: Sales decline may indicate market challenges or competitive pressures.

Analysis: Negative revenue growth requires analysis of market conditions.

Limited Growth History (-15.48% CAGR)

Observation: Below-average 5-year sales growth trajectory.

Analysis: Low sales CAGR may indicate mature markets or limited growth opportunities.

Elevated Debt Levels (D/E: 1.48)

Observation: High leverage increases financial risk and interest burden.

Analysis: High debt-to-equity ratios require monitoring of debt servicing capability.

Weak Interest Coverage (0.09x)

Observation: Limited ability to service debt obligations from earnings.

Analysis: Low interest coverage raises concerns about financial stability.

Limited Institutional Interest (FII+DII: 0.04%)

Observation: Low institutional participation may affect liquidity.

Analysis: Limited institutional interest may indicate size constraints or visibility issues.

No Dividend Distribution

Observation: Company does not currently pay dividends to shareholders.

Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.

Bilcare Ltd vs Healthcare Research, Analytics & Technology Peers

Peer Comparison - Healthcare Research, Analytics & Technology

Compare Bilcare Ltd with 8 other companies in the same sector

9 companies
Company Info
Fundamental
Valuation
Profitability
Financial Health
Growth
Dividend
Company
Company name
Score
Bull Run comprehensive fundamental score based on 20+ metrics
Price
Current trading price of the stock
Market Cap
Total value of all shares in the market
P/E
Price per share divided by earnings per share
ROE
Net income divided by shareholder equity
ROCE
Earnings before interest and tax divided by capital employed
Debt/Eq
Total debt divided by total equity
Profit 5Y
Average annual profit growth over 5 years
Sales 5Y
Average annual sales growth over 5 years
Dividend
Annual dividend per share divided by price per share
6.9/100
58
₹200.42
-5.58%
Poor
1.10%
Poor
1.5
Average
13.81%
Good
-15.48%
Poor
0.00%
41.6/100
460
₹25985.68
55.5
Average
10.53%
Average
13.52%
Average
0.1
Excellent
5.71%
Good
12.60%
Good
0.19%
66.8/100
519
₹12660.10
28.4
Average
20.59%
Excellent
24.80%
Excellent
0.0
Excellent
67.93%
Excellent
34.59%
Excellent
0.38%
6.5/100
267
₹3927.58
-87.22%
Poor
-86.96%
Poor
0.0
Excellent
-24.19%
Poor
-12.00%
Poor
0.00%
65.8/100
457
₹2716.50
36.4
Average
19.43%
Good
25.22%
Excellent
0.0
Excellent
58.03%
Excellent
13.74%
Good
0.16%
19.5/100
31
₹481.24
120.6
Average
644.12%
Excellent
11.24%
Average
0.0
Excellent
38.14%
Excellent
0.00%
40.6/100
57
₹101.70
104.8
Average
0.64%
Poor
0.96%
Poor
0.0
Excellent
-2.33%
Poor
82.92%
Excellent
0.00%
29.2/100
18
₹25.54
12.3
Average
5.51%
Poor
8.27%
Poor
0.2
Excellent
-1.36%
Poor
8.33%
Good
0.00%
7.2/100
24
₹16.84
-37.24%
Poor
-11.58%
Poor
1.6
Average
-32.27%
Poor
0.00%

Bilcare Ltd Quarterly Performance

Latest quarterly metrics for BI — revenue growth and profit growth vs same quarter last year

Revenue Growth (YoY)

-11.67%

Latest quarter vs same quarter previous year

Net Profit Growth (YoY)

-15.39%

Latest quarter net profit vs same quarter previous year

5-Year Revenue CAGR

-15.48%

Compounded annual revenue growth over 5 years

5-Year Profit CAGR

13.81%

Compounded annual net profit growth over 5 years

Bilcare Ltd Technical Indicators

SMA 50, SMA 200, RSI and volume signals for BI — calculated from daily price history

36RSI 14
Neutral — RSI 36

Momentum is balanced — neither overbought nor oversold.

SMA 50
61
▼ Price below SMA 50 — Short-term bearish
SMA 200
74
▼ Price below SMA 200 — Long-term downtrend
30-Day Avg Volume
7K shares/day
Average daily traded volume over last 30 trading sessions

Technical indicators are for educational purposes only. Not investment advice.

Bilcare Ltd Financial Statements

Annual income statement, balance sheet and cash flow for Bilcare Ltd (BI) — sourced from NSE/BSE filings.

Loading Financial Statements...

Fetching financial data for Bilcare Ltd

About BI (Bilcare Ltd)

Bilcare Ltd is a pioneering force at the intersection of healthcare research, analytics, and technology, dedicated to enhancing pharmaceutical integrity and patient safety globally.... The company distinguishes itself through its commitment to developing advanced packaging solutions that transcend traditional protective measures. Bilcare's multifaceted approach encompasses sophisticated research into material science, focusing on crafting innovative films, foils, and laminates specifically engineered to safeguard the efficacy and stability of solid-dose medications. Beyond mere physical protection, Bilcare is intensely invested in developing advanced anti-counterfeiting technologies and track-and-trace systems, empowering manufacturers to combat the pervasive threat of counterfeit drugs and ensure the authenticity of their products from production to patient consumption. Beyond its packaging solutions, Bilcare extends its expertise into the realm of clinical trial support. Bilcare facilitates the smooth execution of clinical studies through comprehensive trial management, tailored supplies, and logistical support. The company leverages cutting-edge data analytics to derive actionable insights from clinical trial data, accelerating the drug development process and improving trial outcomes. By integrating research, advanced data analytics, and innovative technologies, Bilcare plays a vital role in driving efficiency and transparency in clinical research. This holistic approach reinforces its position as a trusted partner for pharmaceutical companies seeking to navigate the complexities of drug development and regulatory compliance. Furthermore, Bilcare aggressively pursues research and development initiatives to push the boundaries of healthcare technology. It's a forward-thinking company aiming to revolutionize healthcare through material science, data, and pharmaceutical integrity. These ventures are fueled by a deep understanding of the evolving healthcare landscape and the escalating challenges faced by pharmaceutical manufacturers and patients. Bilcare invests in exploring new materials, developing advanced data analytics tools, and creating sophisticated track-and-trace technologies. This emphasis on innovation ensures that Bilcare remains at the forefront of the industry, consistently delivering cutting-edge solutions that address emerging needs and advance the frontiers of pharmaceutical integrity and patient safety.

Company Details

Symbol:BI
Industry:Healthcare Research, Analytics & Technology
Sector:Healthcare Research, Analytics & Technology

Key Leadership

Mr. Mohan Harakchand Bhandari
Chief Executive Officer
Ms. Deepa Mathur
Chief Financial Officer
Mr. Sagar R. Baheti
Company Secretary & Compliance Officer

BI Share Price: Frequently Asked Questions

What is the current share price of Bilcare Ltd?

Bilcare Ltd (BI) trades at ₹58.00 on NSE and BSE. Market cap ₹200.42 (Cr). Educational data only.

What is the P/E ratio of Bilcare Ltd?

Bilcare Ltd has a P/E of N/Ax vs industry average 45.95x.

What is the Bull Run score for Bilcare Ltd?

Bilcare Ltd has a Bull Run score of 6.9/100 based on 25+ financial parameters.

Does Bilcare Ltd pay dividends?

Bilcare Ltd has a dividend yield of 0.00%. Past dividends don't guarantee future payments.

What is the ROE of Bilcare Ltd?

Bilcare Ltd has ROE of -5.58%. Higher ROE indicates better use of shareholder equity.

What is the debt-to-equity ratio of Bilcare Ltd?

Bilcare Ltd has debt-to-equity of 1.48.

Is Bilcare Ltd a good investment?

Bull Run gives Bilcare Ltd a score of 6.9/100. This is not investment advice — consult a SEBI-registered advisor.